Effects of estradiol and progestogens on human breast cells: Regulation of sex steroid receptors  by Chen, Fang-Ping et al.
Available online at www.sciencedirect.comScienceDirect
Taiwanese Journal of Obstetrics & Gynecology 52 (2013) 365e373
www.tjog-online.comOriginal Article
Effects of estradiol and progestogens on human breast cells: Regulation
of sex steroid receptors
Fang-Ping Chen a,*, Mei-Hua Chien a, Huang-Yang Chen b, Ting-Shuo Huang b, Yuet-Tong Ng c
aDepartment of Obstetrics and Gynecology, Keelung Chang Gung Memorial Hospital and Chang Gung University, Taiwan
bDepartment of General Surgery, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan
cDepartment of Anesthesiology, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan
Accepted 18 September 2012AbstractObjectives: To examine the effects of 17b-estradiol (E2) and progestogens, used in hormone therapy, on estrogen receptors (ER), progesterone
receptors (PR), and human breast tumor cell growth.
Materials and methods: MCF-7 cells were incubated in pure E2 (1 nM and 10 nM) as well as in E2 in conjunction with 10 nM progestogens,
including progesterone (P4), medroxyprogesterone acetate (MPA), norethisterone acetate (NET), and cyproterone acetate (CPA). Cell prolif-
eration, apoptosis, expression of caspase-3, and both ER and PR isoforms were evaluated.
Results: Caspase-3 was significantly diminished in cultures with only E2, whereas ERa significantly increased. A significant increase of caspase-
3 in addition to the entire abolishment of E2-induced augmentation of ERa was observed in 1 nM E2 plus MPA and 10 nM E2 plus NET, whereas
PR isoform B (PRB) was significantly increased. The ratios of apoptosis: proliferation significantly increased in 1 nM E2 plus progestogens
(except P4) and 10 nM E2 plus NET. The changes of the PRA/PRB ratio were inversely related to the changes of the apoptosis to proliferation
ratio. Significant increase of ERb and PRB was noted in the E2 plus MPA or NET, in addition to a significant increase of ERa and decrease of
PRA in the E2 plus CPA, as well as an increase of ERa and decrease of PRA and PRB in the E2 plus P4.
Conclusions: The combination of E2 and various progestogens resulted in diverging effects on ERs and PRs expressions, which induced different
effects on MCF-7 cell growth. Compared with P4, aberrant hormone and biological activity of synthetic progestin, by way of altered receptor
expression, may be an important factor in affecting breast cell growth.
Copyright  2013, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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The expression of sex steroid receptors in breast cancer
tissue has been recognized as being able to predict the clinical
response to endocrine treatments. Knockout of the estrogen
receptor (ER) and progesterone receptor (PR) genes prevents
complete mammary gland development in mature mice [1,2].
Thus, the effects of estrogen and progesterone on the mam-
mary gland are believed to be mediated by their ER and PR.* Corresponding author. Department of Obstetrics and Gynecology, Keelung
Chang Gung Memorial Hospital, 222 Mai-Chin Road, Keelung, Taiwan.
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http://dx.doi.org/10.1016/j.tjog.2012.09.038However, the exact mechanisms by which estrogen and pro-
gestestogens regulate the proliferation and differentiation of
human breast cells remains less known.
It is generally accepted that female sex hormones are linked
to the etiopathogenesis of breast cancer. Results from a large
randomized clinical trial, the Women’s Health Initiative,
indicate a poorer outlook in users of combined estrogen-
progestin therapy, represented by a larger proportion of tu-
mors with lymph-node metastases and by differentiated tu-
mors [3,4]. By contrast, observational studies have repeatedly
reported fewer malignant clinical features and improved
prognosis in hormone therapy (HT) users [5,6]. However, the
impact of HT use on breast-cancer prognosis and clinicalcs & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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periments and observations in women suggest, the treatment
with estrogen/progestogen may have diverging effects on the
expression of ER and PR isoforms in the breast epithelium [7].
In order to investigate the mechanisms of the HT agents and
the applicability of combined HT for breast cancers, we
studied the effects of estrogen and various progestogens on
ER, PR, and cell growth in MCF-7 human breast cancer cells.
Materials and methodsEthicsThis study was approved by the Ethical Medicine Com-
mittee of Chang Gung Memorial Hospital and supported by
the Clinical Monitoring Research Program (CMRP) of Chang
Gung Memorial Hospital at Keelung.Cell cultureMCF-7 cells were obtained from the American Type Cul-
ture Collection (ATCC, Manassas, VA, USA). MCF-7 cells
were cultured in serum-free medium for 12 hours and then
treated with pure 17b-estradiol (E2 1 nM and 10 nM; Sigma,
St Louis, MO, USA), as well as E2 (1 nM and 10 nM) com-
bined with various progestogens (10 nM), including proges-
terone (P4; Sigma), cyproterone acetate (CPA; Sigma),
norethisterone acetate (NET; EPS, Strasbourg, France), and
medroxyprogesterone acetate (MPA; United States Pharma-
copeia, Rockville, MD, USA). After further incubation for 12
hours, the cells were harvested and extracted for analysis.Measurement of cell deathCell death (apoptosis) was measured by terminal deoxy-
nucleotidyl transferase mediated dUTP nick end labeling
(TUNEL). MCF-7 cells grown on a 6 mm plate were washed
twice with PBS and fixed for 30 minutes in 4% buffered
paraformadelhyde. The cells were then incubated with 0.1%
Triton X-100 in a 0.1% sodium citrate solution for 8 minutes,
washed in phosphate-buffered saline, and incubated with ter-
minal deoxynucleotidyl transferase for 90 minutes and fluo-
rescein isothiocyanate-dUTP for 30 minutes at 37 C using an
apoptosis detection kit (Roche Applied Science, Indianapolis,
IN, USA). Samples, in a drop of PBS, were analyzed under a
fluorescence and UV light microscope at this state by using an
excitation wavelength in the range of 450e500 nm and
detection in the range of 515e565 nm (green).Measurement of proliferationFor the cell proliferation assay, 100 mL passaged MCF-7
(1  104 cells/mL) were seeded into 96-well plates contain-
ing DMEM with 10% FBS and allowed to adhere for 24 hours.
Then, the cells were treated with E2 (1 nM and 10 nM) and E2
plus progestogens (10 nM) and allowed to proliferate for 12
hours. A 100 mL aliquot of 5-bromo-20-deoxyuridine (BrdU)labeling solution (10 mM final concentration) was added to
each well, which was then incubated for another 12 hours. At
the end of incubation, the proliferation was determined by the
extent of the incorporated BrdU using an enzyme-linked
immunosorbent assay (ELISA) kit (Cell Proliferation
ELISA, BrdU Colorimetric kit; Roche Applied Science).Protein extraction and western blot analysisCultured MCF-7 cells were scraped and washed once with
PBS. The cell suspension was then centrifuged. The cell pellets
were dissolved for 30 minutes in lysis buffer (50 mM Tris, pH
7.5, 0.5 M NaCl, 1.0 mM EDTA, pH 7.5, 10% glycerol, 1 mM
basal Eagle medium, 1% Igepal-630, and proteinase inhibitor
cocktail tablet) (Roche Applied Science) and then centrifuged
at 12,000  g for 10 minutes. The supernatants were removed
and placed in new Eppendorf tubes for western blot analysis.
Proteins from the MCF-7 cell line were separated in a 12%
gradient SDSePAGE and then transferred onto nitrocellulose
membranes. Nonspecific protein binding was blocked in
blocking buffer at RT for 1 hour (5% milk, 20 mM TriseHCl,
pH 7.6, 150 mM NaCl, and 0.1% Tween 20). The membranes
were blotted with Caspase-3 (Chemicon, Temecula, CA, USA),
phosphorylated PRA/PRB (Cell Signaling Technology, Bev-
erly, MA, USA), phosphorylated ERa (Upstate Biotechnology,
Lake Placid, NY, USA), ERb (Santa Cruz Biotechnology, Santa
Cruz, CA, USA), and b-actin (Millipore, Billerica, MA, USA),
and then incubated in a 4 C blocking buffer overnight.
Densitometric analysis of immunoblots was performed using
the Bio-Rad molecular imager versadoc MP 4000 system (Bio-
Rad, Hercules, CA, USA). Experiments were performed in
triplicate. Western blots were performed to detect the expres-
sions of the isoforms ERa, ERb, PRA, and PRB.Statistical analysisProliferation, cell death, and other parameters were
measured versus controls and performed in triplicate. Statis-
tical significance of difference was calculated using Student t
test for paired data with the level of significance selected at
p < 0.05.
ResultsEffects of sex steroid on breast cell growthThe effect of 17b-estradiol (E2) with or without various
progestogens (including P4, MPA, NET, and CPA) on the
apoptosis to proliferation (A/P) ratio in the MCF-7 cell line is
illustrated in Fig. 1. Compared with the control group, pure E2
had no significant effect on the A/P ratio. In combination with
1 nM E2, the ratio significantly increased when progestogens
( p < 0.001, p < 0.05, vs. control), except P4, were added.
10 nM E2 combined with NET also significantly increased the
ratio ( p < 0.001 vs. control).
To further determine whether the changes in the MCF-7
tumor cells were associated with changes in the apoptotic
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Fig. 2. Caspase-3 proteins levels in the MCF-7 cell line after treatment with 1n
*p < 0.001, **p < 0.05, vs. control. C ¼ control; D ¼ dimethylsulfoxid
CPA ¼ cyproterone acetate; P4 ¼ progesterone.
A/
P 
ra
tio
0
1
2
3
4
5
6
C MPA NET CPA P4 E2D
*
*
**
*
Normal
E2 10nM
E2 1nM
Progestogens + E2 10nM
Progestogens + E2 1nM
Fig. 1. Mean of the ratio of apoptosis to proliferation (A/P ratio) in the MCF-7
cell line after treatment with 1nM or 10nM E2 estradiol (E2) with or without
10nM various progestogens. *p < 0.001, ** p < 0.05, vs. control. C ¼ control;
D ¼ dimethylsulfoxide control; MPA ¼ medroxyprogesterone acetate;
NET ¼ norethisterone acetate; CPA ¼ cyproterone acetate; P4-progesterone.
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an irreversible induction of apoptosis as well as being a marker
of apoptosis. As shown in Fig. 2, caspase-3 proteins levels
diminished significantly when cells were treated with E2 alone
( p< 0.05 vs. control) and this effect was completely reversed in
the presence of progestogens. Significant increase in the
caspase-3 protein content was noted in cells treated with MPA
plus 1 nM E2 and 10 nM E2 plus NET ( p < 0.05, vs. control).Hormonal regulation of PRA and PRBAs shown in Fig. 3A, the PRA/PRB ratio showed no sig-
nificant changes in cells treated with E2 alone, but was reduced
by combined E2 and progestogen. In contrast to the changes of
the A/P ratio, the PRA/PRB ratio was significantly reduced by
the combined 1 nM E2 with progestogens ( p < 0.05 vs.
control), except P4. The combination of 10 nM E2 and NET
also significantly decreased the PRA/PRB ratio ( p < 0.05 vs.
control), whereas other progestogens combined with 10 nM E2
did not show any significant effect on the ratio. However, the   – +       – +        – +      –
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Fig. 3. Effects of 1nM or 10nM E2 estradiol (E2) with or without 10nM various progestogens on (A) PRA/PRB ratio, as well as on the levels of (B) PRA and (C)
PRB phosphorylation in the MCF-7 cell line. *p < 0.001, **p < 0.05, vs. control. C ¼ control; D ¼ dimethylsulfoxide control; MPA ¼ medroxyprogesterone
acetate; NET ¼ norethisterone; CPA ¼ cyproterone acetate; P4 ¼ progesterone.
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the changes of the A/P ratio.
As shown in Fig. 3B, E2 alone had no effect on the
expression of PRA and PRB. The PRA expression signifi-
cantly increased in 10 nM E2 combined with MPA ( p < 0.05
vs. control), but significantly diminished in the combination of
E2 and P4 ( p < 0.05 vs. control), as well as 1 nM E2 plus CPA
( p < 0.05 vs. control). The PRB expression significantly
increased in E2 combined with MPA or NET ( p < 0.001,
p < 0.05 vs. control), but significantly diminished in the 1 nME2 plus P4 ( p < 0.05, vs. control; Fig. 3C). The coordinated
expression of PRA and PRB caused the change of PRA/PRB
ratio in the combination of E2 and various progestogens. E2
combined with MPA or NET induced higher concentration of
PRB than those combined with CPA and P4.Hormonal regulation of ERa and ERbAs shown in Fig. 4A, the expression of ERa phosphory-
lation significantly increased following the administration of
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Fig. 3. (continued).
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well as in 1 nM E2 combined with NET ( p < 0.05 vs. control)
and 10 nM E2 combined with CPA ( p < 0.001 vs. control).
Using 10 nM E2 alone resulted in a 4e5-fold increase in the
expression of ERa phosphorylation, but the effect was
downregulated by the addition of progestogens, especially in
MPA. The expression of ERb had nonsignificant changes in
various hormone treatments, except for a significant increase
in 1 nM E2 combined with MPA or NET and 10 nM E2
combined with MPA ( p < 0.05 vs. control; Fig. 4B). E2
combined with MPA or NET induced higher concentrations of
ERb, while E2 alone and E2 combined with CPA or P4 inducedmore prominent changes in the expression of ERa
phosphorylation.
Discussion
This study demonstrates that various progestogens com-
bined with E2 had different effects on breast cell growth.
These effects had an inverse correlation with the changes of
the PRA/PRB ratio. E2’s antiapoptotic effects on MCF-7 cells
may be related to the expression of ERa phosphorylation. The
antiapoptotic effect of E2 alone was counteracted by the
combination of progestogens, especially at low concentrations
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Fig. 4. Effects of 1nM or 10nM E2 estradiol (E2) with or without 10nM various progestogens on the levels of (A) ERa phosphorylation and (B) ERb in the MCF-7
cell line. *p < 0.001, ** p < 0.05, vs. control. C ¼ control; D ¼ dimethylsulfoxide control; MPA ¼ medroxyprogesterone acetate; NET ¼ norethisterone;
CPA ¼ cyproterone acetate; P4 ¼ progesterone.
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doses of E2 may be more suitable with respect to lowering
breast cancer risk. In addition, our findings suggest that syn-
thetic progestins combined with E2 induced more prominent
changes in the expression of ERs and PRs than the proges-
terone plus E2. Its significance on the effects of breast cells
during HT should be considered.
In breast cancer cell lines, cell death induced by anties-
trogen treatment [8] and inhibition by E2 [9] has been re-
ported. Like the present study, pure E2 significantly decreased
the expressions of caspase-3. An inhibitory effect of E2 on
caspase-3 level was also noted in the report of Somaı¨ et al[10]. In the current study, pure E2 induced antiapoptosis of
MCF-7 cells, in which ERa expression was increased, whereas
the expressions of ERb, PRA, and PRB were not altered. This
is compatible with several reports in that estrogen may induce
anti-apoptotic effects in ERa-positive breast cancers [11,12]
and that the effects may be mediated by ERa.
This study has also shown that 1 nM E2 plus MPA and
10 nM E2 plus NET significantly increased caspase-3
expression and entirely abolished E2-induced augmentation
of ERa expression. It is compatible with other reports that
progestin can inhibit the expression of ER gene transcription
[13,14]. In addition, our results also reveal that PRB
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did not change, in the culture with 1 nM E2 plus MPA and
10 nM E2 plus NET. This demonstrates that MPA and NET
inhibiting E2-induced transcription may be triggered by PRB.
Similar findings were also reported by Chalbos and Galtier
[15], in which synthetic progestin R5020 inhibited estradiol-
induced pS2 levels in MCF-7 cells whereas PRB, but not
PRA, inhibited the gene transcription induced by ER.
Although in the present study, significant increase of ERa
expression was still noted in E2 plus CPA or P4, the decreased
caspase-3 expression by E2 was entirely limited. In contrast to
the increased PRB expression in E2 combined with MPA and
NET, E2 plus CPA or P4 induced no change of PRB nor
decreased PRA and PRB. The present study demonstrates that
decreased ERa, mediated by increased PRB expression, may
induce apoptosis of breast cancer cells.
In the present study, the A/P ratio in the MCF-7 cell line
was significantly increased by the combination of 1 nM E2 andTable 1
Concentrations of progestogens and 17b-estradiol of published studies inhibiting b
Study Model Progestogens
Cappelletti et al [16] MCF-7 and T47D cells stimulated by
various growth factors
MPA 0.1 mM
P4 0.1 mM
Seeger et al [17] MCF-7 cells MPA 10 mM
P4 10 mM
Seeger et al [18] MCF-7 and HCC1500 cells stimulated
by growth factors
MPA 0.1 mM
NET 0.1 mM
Kra¨mer EA et al [19] HCC1500 cells cultured with growth
factors
MPA 0.1 mM
NET 0.1 mM
Mueck AO et al [20] MCF-7 cells cultured with 0.1 nM E2 MPA, P4, and
1 nM, 0.1 mM
MPA ¼ medroxyprogesterone acetate; NET ¼ norethisterone acetate; P4 ¼ progeprogestogens, except P4, as well as by10 nM E2 combined
with NET. The similar findings were also noted by several
reports [16e20] in which progestogens combined with E2
significantly increased the cell death to proliferation ratio, in
comparison with using E2 alone. In addition, the PRA/PRB
ratio was significantly reduced through combined use of 1 nM
E2 with progestogens, except P4, and by the combination of
10 nM E2 and NET as well. The PRA/PRB ratio was inversely
correlated with the changes of the A/P ratio. This reveals that
the response of MCF-7 cells to the effects of combined E2 and
progestin may be modulated via alterations in the ratio of PR-
A and B expression. Hopp et al [21] also found that the
regulated expression of PRA and B is critical to the mammary
gland’s response to progesterone. In addition, the effects of P4
plus E2 on ERs and PRs were similar to using E2 alone, but
were different from using synthetic progesterones plus E2.
Because the combination of E2 and P4 maintained the normal
proliferation rate like the control group did, whetherreast cancer cell growth.
(P) dose 17b-estradiol
(E2) dose
Results
and 1 mM 10 nM Inhibit cell growth with P þ E2
0.1 nM Inhibit cell proliferation with sequential
or continuous P þ E2
and 1 mM
and 1 mM
0.1 nM Decrease in the ratio of apoptosis and
proliferation
and 1 mM
and 1 mM
0.1 nM Inhibit cell proliferation with P þ E2
NET: 0.01 nM,
, and 10 mM
0.1 nM Inhibit E2-stimulated growth only by
adding 10 mM progestogens
sterone.
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mediate the antiapoptosis of E2 or not should be considered.
A French cohort study reported that micronized proges-
terone or didrogesterone used with oral or percutaneous
estradiol showed no increase or decrease in the risk of breast
cancer compared to synthetic progestins for at least 4 years of
treatment [22] and even after 8 years [23]. Although the results
of the present study, except E2 plus P4, were completely
opposite to those of the French cohort study, it demonstrates
that various progestogens have different effects on breast cells,
as well as on the expression of ERs and PRs. Significantly
increased expression of ERb and PRB was noted in E2 com-
bined with MPA or NET, whereas a significant increase of
ERa expression and decrease of PRB and/or PRA in the E2
combined with P4 or CPA was also noted. Because the major
difference of these four progestogens in regards to biologic
activity is the strong androgenic effects of MPA and NET and
glucocorticoid effects of MPA and CPA, evident when
compared with P4, further evaluation is needed to determine
whether the androgen and glucocorticoid receptors also play
important roles as additional cofactors on the expression of
ERs and PRs, as well as on the effects of breast cell growth.
In this decade, although there have been many studies
focusing on the effects of different progestogens plus E2 on
breast cancer cell growth, the major differences in the present
study were the concentrations of progestogens and E2
(Table 1) and the cell preparation. Because our goal was to
examine the effects of E2, with or without progestogens
commonly used for HT, on breast cells, breast cells were
cultured by serum deprivation and growth factors withdrawal
to mimic an aging system. The clinically relevant blood con-
centrations of E2 for achieved HT range 50e200 pg/mL,
equivalent to a concentration of 0.01e0.1 nM [20]. However,
it is well recognized that estrogens are synthesized in the
breast tissue, and especially in tumor tissue, at concentrations
that are remarkably higher than blood levels achieved under
HT [24]. In addition, the clinically relevant blood concentra-
tions of progestogens in this study are in the region of 10 nM
progesterone when administered in a dosage of 200 mg/day
[25], and in the range of 4e10 nM for MPA [26] and around
10 nM for NET [27]. Thus, 10 nM progestogens and higher
concentration of 1 nM and 10 nM E2 were used in this
experiment. Table 1 reveals that most of the other studies
demonstrate similar results with higher pharmacological doses
of progestogens. In addition, there are few data available to
evaluate the effects of progestogens (especially CPA) plus E2
on breast cancer cell growth and the expression of sex steroid
receptor subtypes simultaneously like the present study.
In conclusion, the present study demonstrates that E2’s
antiapoptotic effects are significantly reduced by coadminis-
tration of progestogens. The combination of E2 and pro-
gestogens resulted in diverging effects on the expressions of
ERs and PRs, which induced different effects on the cell
growth of MCF-7 cells. Our results in the MCF-7 cells showed
that E2-abrogating apoptosis is mediated by ERa and that the
regulated expression of PRA and PRB is critical to the breast
cells’ response to synthetic progesterone. The effect of P4 onbreast cells and the expression of ERs and PRs are different
from that of synthetic progestins. Thus, the present study re-
veals that aberrant hormone activity, by way of altered re-
ceptor expression, may be an important factor in the malignant
transformation of breast cells.
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